This ADC product is comprised of an anti-CD33 monoclonal antibody (h2H12ec) conjugated via a Mc-VC linker to SGD-1882. The SGD-1882 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, SGD-1882 binds to DNA, causes DNA damage.
CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins.
ADC Antibody
Overview
Humanized Anti-CD33 Antibody, h2H12ec
Generic name
h2H12ec
Species Reactivity
Human
ADC Linker
Name
mc-VC (maleimidocaproyl-valine-alanine)
Description
Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
ADC payload drug
Name
SGD-1882
Description
Pyrrolobenzodiazepine (PBD) dimmers are highly cytotoxic DNA cross-linking agents. PBDs exert their biological activity through covalent binding via their N10-C11imine/carbinolamine moieties to the C2-amino position of a guanine residue within the minor groove of DNA.